return to news
  1. Upstox
    /
  2. News
    /
  3. Market News
    /
  4. Stocks
    /
  5. Wockhardt shares soar over 12% as loss turns to profit in Q4, EBITDA surges 147% YoY; key details to know

Market News

Wockhardt shares soar over 12% as loss turns to profit in Q4, EBITDA surges 147% YoY; key details to know

Abha Raverkar
By Abha Raverkar

3 min read | Updated on May 05, 2026, 11:33 IST

Google
SelectUpstoxas yourPreferred news source
Copy link
Twitter Page
Linkedin Page
Whatsapp Page

SUMMARY

Wockhardt Q4 results: Its revenue from operations soared 30% YoY to ₹965 crore in the March quarter of FY26, as against ₹743 crore in the year-ago period.

Stock list

WOCKPHARMA
--
Wockhardt

Its EBITDA margin expanded to 20.3% in Q4 FY26, compared with 19.5% in the same period last year. | Image: Shutterstock

Wockhardt share price: Shares of Wockhardt soared as much as 12.55% to hit an intraday high of ₹1,603.90 apiece on the National Stock Exchange (NSE) on Tuesday, May 5, after the company announced its earnings for the January-March quarter of the 2025-26 financial year (Q4 FY26).
Open FREE Demat Account within minutes!
Join now

At around 11:26 AM, the stock was trading 9.37% higher at ₹1,558.50 per equity share.

The scrip has jumped 12% in the past week and 25% over the month. On a year-to-date basis, it has advanced 11%.

While the share hit a 52-week high of ₹1,868.80 per unit on June 15, 2025, it touched a year’s low of ₹1,086.70 on March 23, 2026.

Wockhardt Q4 results

The company recorded a consolidated net profit of ₹166 crore during the quarter under review, compared to a loss of ₹25 crore in the fourth quarter of the 2024-25 fiscal year (Q4 FY25), according to a regulatory filing dated May 4.

During the quarter, pursuant to the settlement agreement with Dr. Reddy’s, Wockhardt agreed to receive ₹35.35 crores towards full and final settlement of all obligations under a business transfer agreement (BTA).

Additionally, during the quarter, the Group executed a settlement agreement with the Chapter 7 trustee for the bankruptcy estate. Accordingly, a net charge of ₹12.70 crore was recognised under exceptional items towards the settlement amount.

The pharmaceutical and biotechnology major’s revenue from operations soared 30% year-on-year (YoY) to ₹965 crore in the March quarter of FY26, as against ₹743 crore in the year-ago period.

At an operational level, its EBITDA (earnings before interest, tax, depreciation and amortisation), also known as operating profit, stood at ₹196 crore for the reporting quarter, marking a 147% YoY surge from ₹79 crore in Q4 FY25.

Its EBITDA margin expanded to 20.3% in Q4 FY26, compared with 19.5% in the same period last year.

Region-wise highlights

Wockhardt’s revenue from its India-branded business stood at ₹112 crore in the quarter ended March 31, 2026, reflecting an 18% YoY surge from ₹95 crore in the year-ago period, bolstered by a substantial jump in its branded operations due to performance driven by the Diabetic therapy, NCE (EMROK), and the introduction of the Regenerative Derma segment.
Its revenue from the emerging markets region rose 124% YoY to ₹320 crore for the reporting quarter, as against ₹143 crore in the March FY25 quarter, driven mainly by its Biotech Insulin segment. The Latam operations contributed significant traction to the segment growth, it added.
The UK region clocked a revenue of ₹349 crore in Q4 FY26, showcasing a growth of 20% YoY.
The Irish region saw its revenue growing 12% YoY to ₹52 crore in the March quarter of FY26.

FY26 performance

In FY26, the company posted a consolidated net profit of ₹213 crore, as against a loss of ₹47 crore in the previous fiscal.

The company had an exception item charge of ₹85 crore in FY26, which included one-time charges related to restructuring and regulatory compliance, including the impact of US entity liquidation and the New Labour code.

Its revenue from operations grew 11% You to ₹3,373 crore during the fiscal year under review, compared to ₹3,033 crore in FY25.

It recorded an EBITDA of ₹360 crore, up by 51% YoY from ₹418 crore. Additionally, its EBITDA margin expanded to 18.7%, from 13.8%.

Wockhardt has a total market capitalisation of ₹25,340.65 crore as of May 5, 2026, according to data on the NSE.

Disclaimer: This article is purely for informational purposes and should not be considered investment advice from Upstox. Please consult with a financial advisor before making any investment decisions.

About The Author

Abha Raverkar
Abha Raverkar is a post-graduate in economics from Christ University, Bengaluru. She has a strong interest in the markets and loves to unravel the nitty-gritties of the latest happenings in the world of markets, business, and the economy.

Next Story